354 related articles for article (PubMed ID: 20339117)
1. Trafficking defects and gating abnormalities of a novel SCN5A mutation question gene-specific therapy in long QT syndrome type 3.
Ruan Y; Denegri M; Liu N; Bachetti T; Seregni M; Morotti S; Severi S; Napolitano C; Priori SG
Circ Res; 2010 Apr; 106(8):1374-83. PubMed ID: 20339117
[TBL] [Abstract][Full Text] [Related]
2. Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel.
Wang DW; Crotti L; Shimizu W; Pedrazzini M; Cantu F; De Filippo P; Kishiki K; Miyazaki A; Ikeda T; Schwartz PJ; George AL
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):370-8. PubMed ID: 19808432
[TBL] [Abstract][Full Text] [Related]
3. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
[TBL] [Abstract][Full Text] [Related]
4. Gating properties of SCN5A mutations and the response to mexiletine in long-QT syndrome type 3 patients.
Ruan Y; Liu N; Bloise R; Napolitano C; Priori SG
Circulation; 2007 Sep; 116(10):1137-44. PubMed ID: 17698727
[TBL] [Abstract][Full Text] [Related]
5. A sodium channel pore mutation causing Brugada syndrome.
Pfahnl AE; Viswanathan PC; Weiss R; Shang LL; Sanyal S; Shusterman V; Kornblit C; London B; Dudley SC
Heart Rhythm; 2007 Jan; 4(1):46-53. PubMed ID: 17198989
[TBL] [Abstract][Full Text] [Related]
6. A novel LQT-3 mutation disrupts an inactivation gate complex with distinct rate-dependent phenotypic consequences.
Bankston JR; Sampson KJ; Kateriya S; Glaaser IW; Malito DL; Chung WK; Kass RS
Channels (Austin); 2007; 1(4):273-80. PubMed ID: 18708744
[TBL] [Abstract][Full Text] [Related]
7. Complex interactions in a novel SCN5A compound mutation associated with long QT and Brugada syndrome: Implications for Na+ channel blocking pharmacotherapy for de novo conduction disease.
Liu J; Bayer JD; Aschar-Sobbi R; Wauchop M; Spears D; Gollob M; Vigmond EJ; Tsushima R; Backx PH; Chauhan VS
PLoS One; 2018; 13(5):e0197273. PubMed ID: 29791480
[TBL] [Abstract][Full Text] [Related]
8. A novel SCN5A arrhythmia mutation, M1766L, with expression defect rescued by mexiletine.
Valdivia CR; Ackerman MJ; Tester DJ; Wada T; McCormack J; Ye B; Makielski JC
Cardiovasc Res; 2002 Aug; 55(2):279-89. PubMed ID: 12123767
[TBL] [Abstract][Full Text] [Related]
9. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
[TBL] [Abstract][Full Text] [Related]
10. Novel arrhythmogenic mechanism revealed by a long-QT syndrome mutation in the cardiac Na(+) channel.
Abriel H; Cabo C; Wehrens XH; Rivolta I; Motoike HK; Memmi M; Napolitano C; Priori SG; Kass RS
Circ Res; 2001 Apr; 88(7):740-5. PubMed ID: 11304498
[TBL] [Abstract][Full Text] [Related]
11. Unique mixed phenotype and unexpected functional effect revealed by novel compound heterozygosity mutations involving SCN5A.
Medeiros-Domingo A; Tan BH; Iturralde-Torres P; Tester DJ; Tusié-Luna T; Makielski JC; Ackerman MJ
Heart Rhythm; 2009 Aug; 6(8):1170-5. PubMed ID: 19632629
[TBL] [Abstract][Full Text] [Related]
12. Y1767C, a novel SCN5A mutation, induces a persistent Na+ current and potentiates ranolazine inhibition of Nav1.5 channels.
Huang H; Priori SG; Napolitano C; O'Leary ME; Chahine M
Am J Physiol Heart Circ Physiol; 2011 Jan; 300(1):H288-99. PubMed ID: 21076026
[TBL] [Abstract][Full Text] [Related]
13. Predicting Patient Response to the Antiarrhythmic Mexiletine Based on Genetic Variation.
Zhu W; Mazzanti A; Voelker TL; Hou P; Moreno JD; Angsutararux P; Naegle KM; Priori SG; Silva JR
Circ Res; 2019 Feb; 124(4):539-552. PubMed ID: 30566038
[TBL] [Abstract][Full Text] [Related]
14. Alpha1-syntrophin mutations identified in sudden infant death syndrome cause an increase in late cardiac sodium current.
Cheng J; Van Norstrand DW; Medeiros-Domingo A; Valdivia C; Tan BH; Ye B; Kroboth S; Vatta M; Tester DJ; January CT; Makielski JC; Ackerman MJ
Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):667-76. PubMed ID: 20009079
[TBL] [Abstract][Full Text] [Related]
15. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
[TBL] [Abstract][Full Text] [Related]
16. Effects of temperature and mexiletine on the F1473S Na+ channel mutation causing paramyotonia congenita.
Fleischhauer R; Mitrovic N; Deymeer F; Lehmann-Horn F; Lerche H
Pflugers Arch; 1998 Oct; 436(5):757-65. PubMed ID: 9716710
[TBL] [Abstract][Full Text] [Related]
17. Partial expression defect for the SCN5A missense mutation G1406R depends on splice variant background Q1077 and rescue by mexiletine.
Tan BH; Valdivia CR; Song C; Makielski JC
Am J Physiol Heart Circ Physiol; 2006 Oct; 291(4):H1822-8. PubMed ID: 16632547
[TBL] [Abstract][Full Text] [Related]
18. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology of the long QT syndrome: impact on management.
Priori SG; Napolitano C; Paganini V; Cantù F; Schwartz PJ
Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 2):2052-7. PubMed ID: 9272507
[TBL] [Abstract][Full Text] [Related]
20. A heterozygous deletion mutation in the cardiac sodium channel gene SCN5A with loss- and gain-of-function characteristics manifests as isolated conduction disease, without signs of Brugada or long QT syndrome.
Zumhagen S; Veldkamp MW; Stallmeyer B; Baartscheer A; Eckardt L; Paul M; Remme CA; Bhuiyan ZA; Bezzina CR; Schulze-Bahr E
PLoS One; 2013; 8(6):e67963. PubMed ID: 23840796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
